David Chien

Medicine · Health Sciences

35h-index6.0kcitations87works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(34), Hepatitis B Virus Studies(26), Monoclonal and Polyclonal Antibodies Research(13), Medical Imaging Techniques and Applications(9), Biosimilars and Bioanalytical Methods(8)

Publications87 total

Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2 study.
Journal of Clinical Oncology·2025
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02
European Urology·2022· 17 cited
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
Journal for ImmunoTherapy of Cancer·2022· 26 citedOpen Access
A Phase 2/3, Randomized, Open-Label Study of Bempegaldesleukin Plus Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma with PD-L1-Expressing Tumors (PROPEL-36)
International Journal of Radiation Oncology*Biology*Physics·2022
PIVOT-12: a Phase III Study of Adjuvant Bempegaldesleukin Plus Nivolumab in Resected Stage III/IV Melanoma at High Risk for Recurrence
Future Oncology·2022· 10 citedOpen Access
140P Preliminary results from PROPEL: A phase I/II study of bempegaldesleukin (BEMPEG: NKTR-214) plus pembrolizumab (PEMBRO) with or without chemotherapy in patients with metastatic NSCLC
Annals of Oncology·2021· 1 cited
83P Evaluation of concordance between PD-L1 immunohistochemistry 28-8 and 22C3 pharmDx assays in metastatic urothelial carcinoma (mUC) in PIVOT-10
Annals of Oncology·2021
Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product
Targeted Oncology·2020· 1 citedOpen Access
Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product
Targeted Oncology·2020· 18 citedOpen Access
Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
Clinical Rheumatology·2020Open Access
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer
Future Oncology·2020· 7 citedOpen Access
Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
Clinical Rheumatology·2020· 18 citedOpen Access
A Randomized, Double‐Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis
Clinical Pharmacology in Drug Development·2020· 14 citedOpen Access
Efficacy and safety of ABP 798 compared with rituximab: Results from the comparative clinical study in patients with non-Hodgkin’s.
Journal of Clinical Oncology·2020· 1 cited
A randomized, double‐blind, single‐dose, three‐arm, parallel group study to determine pharmacokinetic similarity of ABP 959 and eculizumab (Soliris<sup>®</sup>) in healthy male subjects
European Journal Of Haematology·2020· 28 citedOpen Access
Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study
Blood·2019· 1 cited
PF347 PHARMACOKINETIC AND PHARMACODYNAMIC SIMILARITY OF ABP 959 WITH ECULIZUMAB: RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, SINGLE-DOSE, PARALLEL-GROUP STUDY IN HEALTHY SUBJECTS
HemaSphere·2019· 1 citedOpen Access
Awareness, Knowledge and Perceptions of Biosimilars among Specialty Physicians
Figshare·2018Open Access
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL‐2 inhibitor, in patients with non‐Hodgkin lymphoma
British Journal of Clinical Pharmacology·2016· 98 citedOpen Access
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
Advances in Therapy·2016· 202 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Michael Houghton(12), George Kuo(11), Angelica Medina-Selby(6), Doris Coit(6), Sergio Abrignani(5), Amy J. Weiner(4), Jang H. Han(4), Domenico Rosa(4), Christine Dong(4), Mark Selby(4), Kin Cheung Ng(4), Shekman Wong(4), Colin S. McCoin(4), Hartmuth C. Kolb(3), Q L Choo(3), Stephen Coates(3), Suresh Agarwal(3), Ahmed Hamed Salem(3), Steve Nguyen(3), Mark Wininger(3)